3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
8
Lymphoma, Follicular
8
Lymphoma
7
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, B-Cell, Marginal Zone
5
Recurrence
4
Myeloproliferative Disorders
4
Lymphoma, Mantle-Cell
4
Primary Myelofibrosis
3
Hereditary Sensory and Autonomic Neuropathies
2
Advanced Malignancies
2
Unresectable or Metastatic Solid Tumors
1
Solid Tumors
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
B-Cell Malignancies
1
Interventions
Cytarabine
21
Imatinib Mesylate
20
venetoclax
16
Azacitidine
16
nilotinib
15
Cyclophosphamide
15
fludarabine
13
Dasatinib
12
blinatumomab
10
Rituximab
10
quizartinib
7
Gemtuzumab
7
Daunorubicin
7
ruxolitinib
6
Drug Therapy
6
Clofarabine
6
Bendamustine Hydrochloride
6
AP 1903 reagent
6
ponatinib
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Vincristine
5
Mycophenolic Acid
5
Methotrexate
5
Granulocyte Colony-Stimulating Factor
5
Dexamethasone
5
vosaroxin
4
revumenib
4
rasburicase
4
forodesine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia
×
parsaclisib
×
Clear all
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts